title: Transcription addiction: can we garner the Yin and Yang functions of E2F1 for cancer therapy?
abstract: Classically, as a transcription factor family, the E2Fs are known to regulate the expression of various genes whose products are involved in a multitude of biological functions, many of which are deregulated in diseases including cancers. E2F is deregulated and hyperactive in most human cancers with context dependent, dichotomous and contradictory roles in almost all cancers. Cancer cells have an insatiable demand for transcription to ensure that gene products are available to sustain various biological processes that support their rapid growth and survival. In this context, cutting-off hyperactivity of transcription factors that support transcription dependence could be a valuable therapeutic strategy. However, one of the greatest challenges of targeting a transcription factor is the global effects on non-cancerous cells given that they control cellular functions in general. Recently, there is growing realization regarding the possibility to target the oncogenic activation of transcription factors to modulate transcription addiction without affecting the normal activity required for cell functions. In this review, we used E2F1 as a prototype transcription factor to address transcription factor activity in cancer cell functions. We focused on melanoma considering that E2F1 executes critical functions in response to UV, an etiological factor of cutaneous melanoma and lies immediately downstream of the CDKN2A/pRb axis, which is frequently deregulated in melanoma. Further, activation of E2F1 in melanomas can also occur independent of loss of CDKN2A. Given its activated status and the ability to transcriptionally control a plethora of genes involved in regulating melanoma development and progression, we review the current literature on its differential role in controlling signaling pathways involved in melanoma as well as therapeutic resistance, and discuss the practical value of weaning melanoma cells from E2F1-mediated transcription dependence for melanoma management.
authors.affiliation: Department of Urology, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
authors.forename: P
authors.initials: P
authors.lastname: Meng
authors.affiliation: 1] Department of Urology, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA [2] Department of Pharmacology, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA [3] Department of Molecular Medicine, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA [4] Cancer Therapy and Research Center, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
authors.forename: R
authors.initials: R
authors.lastname: Ghosh
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000378:metabolism; D019008:Drug Resistance, Neoplasm; D050684:E2F Transcription Factors / Q000378:metabolism*; D006801:Humans; D035683:MicroRNAs / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy*; D011499:Protein Processing, Post-Translational; D016160:Retinoblastoma Protein / Q000378:metabolism; D015398:Signal Transduction; D016709:Yin-Yang
chemical_list: D000970:Antineoplastic Agents; D019941:Cyclin-Dependent Kinase Inhibitor p16; D050684:E2F Transcription Factors; D035683:MicroRNAs; D016160:Retinoblastoma Protein
references.citation: Cancer Discov. 2013 Feb;3(2):182-97
references.pmid: 23306062
references.citation: Int J Oncol. 2001 Aug;19(2):359-65
references.pmid: 11445852
references.citation: Cell. 1996 May 17;85(4):549-61
references.pmid: 8653790
references.citation: Cell Biol Int. 2009 Jun;33(6):640-9
references.pmid: 19289176
references.citation: J Biol Chem. 2004 Dec 24;279(52):54140-52
references.pmid: 15494392
references.citation: J Natl Cancer Inst. 2005 Nov 2;97(21):1589-600
references.pmid: 16264179
references.citation: Nucleic Acids Res. 2011 Mar;39(4):1390-7
references.pmid: 20972224
references.citation: Cancer Res. 2012 Jan 1;72(1):13-7
references.pmid: 22180494
references.citation: Ann N Y Acad Sci. 2006 Dec;1091:270-81
references.pmid: 17341621
references.citation: Cancer. 2010 Sep 15;116(18):4420-32
references.pmid: 20549818
references.citation: Hum Pathol. 2011 Oct;42(10):1505-13
references.pmid: 21496871
references.citation: Trends Biochem Sci. 2004 Aug;29(8):409-17
references.pmid: 15362224
references.citation: Nucleic Acids Res. 2006 Mar 31;34(6):1745-54
references.pmid: 16582100
references.citation: EMBO J. 2012 Apr 4;31(7):1785-97
references.pmid: 22327218
references.citation: Cancer Res. 1997 Nov 1;57(21):4722-6
references.pmid: 9354430
references.citation: J Biol Chem. 1996 Aug 23;271(34):20608-16
references.pmid: 8702807
references.citation: Hepatology. 2002 Jun;35(6):1341-50
references.pmid: 12029619
references.citation: J Exp Med. 2000 Mar 20;191(6):1005-16
references.pmid: 10727462
references.citation: Clin Cancer Res. 2005 Sep 15;11(18):6589-97
references.pmid: 16166437
references.citation: Dis Esophagus. 2004;17(2):150-4
references.pmid: 15230729
references.citation: Cancer Biol Ther. 2012 Sep;13(11):1091-101
references.pmid: 22825328
references.citation: IUBMB Life. 2009 May;61(5):537-43
references.pmid: 19391166
references.citation: EMBO J. 2000 Feb 15;19(4):662-71
references.pmid: 10675335
references.citation: Oncogene. 2003 Jan 16;22(2):161-7
references.pmid: 12527885
references.citation: Cancer Epidemiol Biomarkers Prev. 2000 Apr;9(4):395-401
references.pmid: 10794484
references.citation: Vet Comp Oncol. 2013 Jun;11(2):113-23
references.pmid: 23638671
references.citation: Neoplasia. 2013 Jul;15(7):826-39
references.pmid: 23814494
references.citation: J Biol Chem. 2011 May 13;286(19):16606-14
references.pmid: 21454583
references.citation: Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9903-7
references.pmid: 16777967
references.citation: Oncogene. 2006 Sep 14;25(41):5656-63
references.pmid: 16652153
references.citation: Cancer Cell. 2013 Jul 8;24(1):105-19
references.pmid: 23792190
references.citation: J Biol Chem. 2002 Oct 18;277(42):39760-8
references.pmid: 12149244
references.citation: Oncogene. 2014 Aug 7;33(32):4164-72
references.pmid: 24276245
references.citation: Exp Dermatol. 2008 Dec;17(12):986-91
references.pmid: 18503552
references.citation: Breast Cancer Res Treat. 2003 Nov;82(1):11-6
references.pmid: 14672398
references.citation: Genes Chromosomes Cancer. 2008 Oct;47(10):890-905
references.pmid: 18618715
references.citation: World J Gastroenterol. 2007 Mar 14;13(10):1487-92
references.pmid: 17461438
references.citation: Cancer. 1999 Nov 15;86(10):2021-33
references.pmid: 10570427
references.citation: Cell. 1986 Apr 25;45(2):219-28
references.pmid: 2938741
references.citation: PLoS One. 2012;7(8):e42598
references.pmid: 22880048
references.citation: BMC Res Notes. 2014 Jan 06;7:6
references.pmid: 24393368
references.citation: Cancer Res. 2004 Oct 15;64(20):7263-70
references.pmid: 15492245
references.citation: Carcinogenesis. 2004 Mar;25(3):333-41
references.pmid: 14604889
references.citation: Oncogene. 2012 Feb 16;31(7):828-41
references.pmid: 21743494
references.citation: Cancer Res. 2003 Mar 15;63(6):1420-9
references.pmid: 12649208
references.citation: J Cancer Res Clin Oncol. 2004 Jun;130(6):320-6
references.pmid: 14997382
references.citation: Cell Oncol. 2007;29(4):335-49
references.pmid: 17641417
references.citation: Future Oncol. 2010 Oct;6(10):1643-52
references.pmid: 21062161
references.citation: Future Oncol. 2012 Sep;8(9):1109-20
references.pmid: 23030486
references.citation: Exp Cell Res. 1999 Dec 15;253(2):561-72
references.pmid: 10585280
references.citation: Ann Surg Oncol. 2013 Nov;20(12):4041-54
references.pmid: 22911364
references.citation: FASEB J. 2003 Apr;17(6):569-74
references.pmid: 12665469
references.citation: Mol Cancer. 2008 Mar 26;7:28
references.pmid: 18366791
references.citation: Mol Cell Biol. 2013 Dec;33(23):4685-700
references.pmid: 24081328
references.citation: Oncogene. 2001 Mar 29;20(14):1678-87
references.pmid: 11313916
references.citation: PLoS One. 2013 May 29;8(5):e64759
references.pmid: 23734217
references.citation: Cancer J. 2012 Mar-Apr;18(2):142-7
references.pmid: 22453015
references.citation: Biotechniques. 2005 Apr;Suppl:17-23
references.pmid: 16528919
references.citation: Biochim Biophys Acta. 2011 Nov-Dec;1809(11-12):668-77
references.pmid: 21616186
references.citation: J Pathol. 2006 Jun;209(2):220-30
references.pmid: 16538612
references.citation: PLoS One. 2013 Sep 04;8(9):e73436
references.pmid: 24023875
references.citation: Cancer Biol Ther. 2004 Apr;3(4):395-9
references.pmid: 14726656
references.citation: Oncol Rep. 1999 Sep-Oct;6(5):983-7
references.pmid: 10425291
references.citation: Cancer Biol Ther. 2013 Aug;14(8):752-60
references.pmid: 23792571
references.citation: J Thorac Oncol. 2013 Aug;8(8):1102-6
references.pmid: 23857401
references.citation: Mol Cancer Res. 2004 Apr;2(4):203-14
references.pmid: 15140942
references.citation: Cancer Biol Ther. 2006 Apr;5(4):407-12
references.pmid: 16481740
references.citation: J Pathol. 2013 Sep;231(1):117-29
references.pmid: 23744542
references.citation: BMC Cancer. 2007 Jan 30;7:24
references.pmid: 17263886
references.citation: J Investig Dermatol Symp Proc. 1998 Aug;3(1):36-40
references.pmid: 9732055
references.citation: Methods Mol Biol. 2009;542:301-13
references.pmid: 19565909
references.citation: Expert Rev Anticancer Ther. 2007 Jan;7(1):79-88
references.pmid: 17187522
references.citation: Clin Cancer Res. 2007 Dec 1;13(23):6938-46
references.pmid: 18056168
references.citation: Nat Rev Cancer. 2009 Nov;9(11):785-97
references.pmid: 19851314
references.citation: Hepatogastroenterology. 2003 Nov-Dec;50(54):1857-63
references.pmid: 14696419
references.citation: J Pathol. 2004 Jul;203(3):744-53
references.pmid: 15221933
references.citation: J Natl Cancer Inst. 2010 Jan 20;102(2):127-33
references.pmid: 20026813
references.citation: Cell Signal. 2008 Jan;20(1):50-9
references.pmid: 17881189
references.citation: J Clin Pathol. 2008 May;61(5):601-5
references.pmid: 17908803
references.citation: Mol Cell Biol. 2009 Apr;29(8):1989-98
references.pmid: 19188449
references.citation: Nat Cell Biol. 2003 May;5(5):401-9
references.pmid: 12717439
references.citation: Oncogene. 2008 Aug 14;27(35):4860-4
references.pmid: 18408756
references.citation: Cancer Res. 2002 Mar 15;62(6):1776-83
references.pmid: 11912154
references.citation: PLoS One. 2013 Aug 15;8(8):e71670
references.pmid: 23967231
references.citation: Cell Cycle. 2012 Aug 15;11(16):3067-78
references.pmid: 22871739
references.citation: Cell Signal. 2008 Jun;20(6):1221-6
references.pmid: 18396012
references.citation: Cancer Biol Ther. 2011 Dec 15;12(12):1032-49
references.pmid: 22157148
references.citation: J Biol Chem. 2001 Aug 31;276(35):32627-34
references.pmid: 11418595
references.citation: J Pathol. 2013 Oct;231(2):143-6
references.pmid: 23868058
references.citation: Mol Cell Biol. 2003 May;23(9):3287-304
references.pmid: 12697828
references.citation: PLoS One. 2011;6(11):e27231
references.pmid: 22076139
references.citation: Cancer Res. 2010 Jun 15;70(12):4931-40
references.pmid: 20516113
references.citation: Exp Hematol Oncol. 2012 Jul 20;1(1):18
references.pmid: 23210897
references.citation: Ann N Y Acad Sci. 2000 Jun;908:71-84
references.pmid: 10911949
references.citation: Clin Cancer Res. 2001 Nov;7(11):3590-7
references.pmid: 11705881
references.citation: Int J Cancer. 1999 May 17;81(4):535-8
references.pmid: 10225440
references.citation: Virchows Arch. 2012 May;460(5):439-46
references.pmid: 22450712
references.citation: FEBS Lett. 2008 Aug 6;582(18):2793-8
references.pmid: 18625225
references.citation: Cancer Res. 2001 Jul 15;61(14):5636-43
references.pmid: 11454718
references.citation: Dis Esophagus. 2005;18(2):109-13
references.pmid: 16053486
references.citation: J Invest Dermatol. 2009 Jun;129(6):1500-15
references.pmid: 19078992
references.citation: EMBO J. 2006 Oct 18;25(20):4795-807
references.pmid: 17006541
references.citation: Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9625-30
references.pmid: 15983384
references.citation: Carcinogenesis. 2012 Feb;33(2):320-5
references.pmid: 22159227
references.citation: Anticancer Res. 2006 May-Jun;26(3A):1947-56
references.pmid: 16827129
references.citation: Mol Cell. 2010 Jul 9;39(1):152-60
references.pmid: 20603083
references.citation: J Natl Cancer Inst. 1999 May 19;91(10):874-81
references.pmid: 10340908
references.citation: Nat Cell Biol. 2011 Aug 14;13(9):1146-52
references.pmid: 21841792
references.citation: Oncogene. 2002 Feb 21;21(9):1359-69
references.pmid: 11857079
references.citation: Lab Invest. 2012 Oct;92(10):1390-7
references.pmid: 22890556
references.citation: Yonsei Med J. 2005 Oct 31;46(5):597-613
references.pmid: 16259056
references.citation: Mol Cell Biol. 2004 May;24(10):4546-56
references.pmid: 15121871
references.citation: Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10848-53
references.pmid: 12954980
references.citation: Mol Cell. 2013 Oct 10;52(1):37-51
references.pmid: 24076217
references.citation: J Clin Pathol. 2005 Sep;58(9):904-10
references.pmid: 16126868
references.citation: Mol Cell. 2004 Dec 3;16(5):831-7
references.pmid: 15574337
references.citation: Oncol Rep. 2008 Sep;20(3):605-11
references.pmid: 18695912
references.citation: J Gastroenterol. 2000;35 Suppl 12:111-5
references.pmid: 10779229
references.citation: Int J Gynecol Cancer. 2008 May-Jun;18(3):492-8
references.pmid: 17692085
references.citation: Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3705-11
references.pmid: 14506162
references.citation: Br J Cancer. 2012 Jan 31;106(3):553-61
references.pmid: 22223089
references.citation: Anticancer Res. 2004 Sep-Oct;24(5A):3041-7
references.pmid: 15517914
references.citation: Lab Invest. 2012 Jul;92(7):1084-96
references.pmid: 22525428
references.citation: J Pathol. 2002 Oct;198(2):142-56
references.pmid: 12237873
references.citation: Cell Death Differ. 2007 Feb;14(2):254-65
references.pmid: 16645632
references.citation: J Pathol. 2009 Jan;217(1):14-20
references.pmid: 18991331
references.citation: Trends Cell Biol. 2008 Nov;18(11):528-35
references.pmid: 18805009
references.citation: Int J Mol Med. 2000 Jul;6(1):55-63
references.pmid: 10851267
references.citation: Nucleic Acids Res. 2001 Jul 1;29(13):2789-94
references.pmid: 11433024
references.citation: Gene. 2005 Jan 3;344:67-77
references.pmid: 15656974
references.citation: J Cell Mol Med. 2012 Mar;16(3):605-15
references.pmid: 21564512
references.citation: Cell Cycle. 2005 Jul;4(7):930-9
references.pmid: 15917652
references.citation: PLoS One. 2010 Apr 29;5(4):e10409
references.pmid: 20454448
references.citation: Exp Cell Res. 2012 Jun 10;318(10):1146-59
references.pmid: 22484375
references.citation: Cell. 1996 May 17;85(4):537-48
references.pmid: 8653789
references.citation: Oncogene. 2000 Oct 19;19(44):5054-62
references.pmid: 11042693
references.citation: Genes Dev. 2004 Mar 15;18(6):673-86
references.pmid: 15075294
references.citation: Pathol Res Pract. 2003;199(1):23-8
references.pmid: 12650514
references.citation: Oncogene. 2012 Mar 22;31(12):1484-92
references.pmid: 21822300
references.citation: Cancer Cell. 2008 Jan;13(1):11-22
references.pmid: 18167336